Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma

Immix Biopharma, Inc.

FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.
If approved, Immix may receive a Priority Review Voucher (PRV), historically sold for $67M to $350M, transferable to other companies.
IMX-110 is currently in a Phase 1b/2a clinical trial and also has orphan drug designation for soft tissue sarcoma.
Company believes IMX-110 targets all three components of the tumor micro-environment via its SMARxT platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.